23andme

By Dave Muoio October 31, 2018
Yesterday afternoon the FDA announced that it would permit 23andMe to market its Personal Genome Service Pharmacogenetic Reports test. The test offers consumers information on whether they posses one of 33 variants across multiple genes that could impact their body’s ability to metabolize certain medications. The purpose of this test is to inform patients and encourage them to more thoroughly...
By Jonah Comstock September 11, 2018
The Cadillac of gene tests? 23andMe is considering a $749 premium gene test offering, considerably more expensive than the $99 to $199 products the company has offered thus far, CNBC reports. Some users received email notifications about a premium service at that price, but clicking the link did nothing. According to 23andMe, it’s only testing user interest and has no plans for a roll out. In...
By Dave Muoio August 24, 2018
23andMe has emailed developers a warning that an API permitting use of anonymized customer datasets for third-party app development will be shut down in approximately two weeks, CNBC reports. While the raw data will remain available to clinical research partners such as GlaxoSmithKline, which invested $300 million this year to gain access to the genetic testing startup’s DNA database for drug...
By Dave Muoio August 1, 2018
A group of consumer genetic and personal genomic testing companies have released a set of best practices for handling consumers’ personal genetic data. Designed to ensure privacy and promote transparency, the guidelines include a requirement for separate express consent before a company can transfer genetic data to a third party, such as an insurer or employer. “Supporting strong and transparent...
23andMe lands $300 million investment from GlaxoSmithKline

23andMe kits at a Beverly Hills event in 2017. Credit: Matt Winkelmeyer, Getty Images

By Bernie Monegain July 25, 2018
23andMe on Wednesday announced that GlaxoSmithKline has invested $300 million to gain exclusive access to the genetic testing startup’s DNA database.  The deal comes as GlaxoSmithKline amid reports that GSK is weighing the possibility of a company breakup and investors contending that synergies between consumer markets and big pharma are inherently limited and that GSK’s pharmaceuticals business...

Scientist working in the lab at Helix. Photo courtesy of Helix. 

By Laura Lovett June 15, 2018
In the last few years consumer genomics has grown in both its offerings and legitimacy. The industry that was once best known for telling clients if they were Italian or Hungarian is now securing its foothold within the healthcare space.    Whether it is uniting women switched at birth 72-years prior or settling neighborly feuds, consumer genomics have caught the public’s interest. The highest...
By Jonah Comstock January 4, 2018
Consumer gene testing company 23andMe is launching a large online study on the relationship between genetics and weight loss behaviors. Drawing volunteer subjects from its existing customers, the company will investigate three different weight loss strategies in a study that hopes to recruit 100,000 participants. "This is to my knowledge the first example of a genome-wide association study for...
By Jonah Comstock November 7, 2017
FDA Commissioner Scott Gottlieb announced today that the agency intends to make a major change to its regulatory process around direct-to-consumer genetic health risk (GHR) tests. Specifically, the agency is creating a framework that will allow companies to bypass premarket certification for individual tests once they submit to a one-time review of their processes, an approach reminiscent of the...
By Tom Sullivan October 30, 2017
The Scripps Research Institute on Wednesday announced a new smartphone app that can calculate a user’s risk of heart disease. Hospitals will want to keep an eye on the research study that Scripps conducts about the effectiveness of giving patients predictions concerning adverse health events and what impact that could have on influencing healthy behaviors and lifestyle changes. Scripps MyGeneRank...
By Jonah Comstock September 6, 2017
Questions raised about IBM Watson for Oncology. A new report from STAT suggests that IBM has been overpromising and underdelivering with the cancer treatment application of its artificial intelligence engine. The article points out a lack of independent, peer-reviewed studies validating the software, and charges that Watson "doesn’t create new knowledge and is artificially intelligent only in the...
ailavita.com.ua

аналог виагры в аптеке

медицинские препараты для повышения потенции у мужчин